NCT07076680View on ClinicalTrials.gov

A Real-World Study of Elacestrant in Patients With HR+/HER2- Advanced Breast Cancer and ESR1 Mutations

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

July 1, 2027

Conditions
Breast Cancer MetastaticHR+/HER2- Advanced Breast CancerESR1 Gene MutationElacestrant
Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Sponsors
All Listed Sponsors
lead

SciClone Pharmaceuticals

INDUSTRY